Literature DB >> 16999776

Examination of two independent kinetic assays for determining the inhibition of carbonic anhydrases I and II: structure-activity comparison of sulfamates and sulfamides.

Richard P Shank1, David F McComsey, Virginia L Smith-Swintosky, Bruce E Maryanoff.   

Abstract

Enzyme inhibition assays often require deviations from physiological conditions. For carbonic anhydrases, procedures involving native CO(2) and non-native substrates have been used. We compared a native and a non-native substrate in the context of inhibition of human carbonic anhydrases I and II by examining various sulfamate and sulfamide compounds in two kinetic assays: hydration of CO(2) and hydrolysis of 4-nitrophenylacetate. For carbonic anhydrase II, the two assays consistently generated similar K(i) values, with the relative difference between the assays never exceeding 2.5-fold. However, for carbonic anhydrase I there was more variability between the two assays, with K(i) values for three compounds differing by more than 2.5-fold, up to eightfold. In the CO(2) hydration assay, some sulfamates and sulfamides exhibited mixed kinetics or partial inhibition. Our results indicate that K(i) or K(d) values from carbonic anhydrase assays involving non-native substrates should be confirmed by assays that use CO(2) (or HCO), to establish pharmacological relevance. From structure-activity comparisons, the sulfamate is more effective than the sulfamide in inhibiting carbonic anhydrase I and II, but the sulfamate does not confer selectivity. In contrast, the sulfonamide confers selectivity for carbonic anhydrase I (10- to 30-fold). Selectivity for carbonic anhydrase II occurred with the substituted fructose moiety, especially the d-enantiomer (>100-fold).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999776     DOI: 10.1111/j.1747-0285.2006.00423.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  4 in total

1.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

2.  Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.

Authors:  Robert B Raffa; Kristin E Finno; Christopher S Tallarida; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2010-09-19       Impact factor: 4.432

Review 3.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Comments to the Editor Due to the Response by the Supuran Group to Our Article.

Authors:  Bengt-Harald Jonsson; Anders Liljas
Journal:  Biophys J       Date:  2020-12-13       Impact factor: 4.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.